RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES
H7323 expands Rhode Island insurance coverage requirements for contraception across multiple categories of health coverage. Beginning January 1, 2027, individual and group health insurance contracts, nonprofit hospital and medical service corporation plans, health maintenance organization plans, and Medicaid coverage would be required to cover FDA-approved contraceptive drugs, devices, and other products, along with voluntary sterilization, related clinical services, and follow-up care. The bill also requires coverage of therapeutic equivalents when available, point-of-sale coverage for over-the-counter contraceptives without a prescription trigger, and up to a 12-month supply of covered contraception when prescribed.
The bill prohibits deductibles, copayments, coinsurance, and other cost-sharing for the required contraceptive coverage, subject to a limited accommodation for qualifying high-deductible health plans tied to federal HSA rules. It also bars utilization management or other restrictions that would limit access, requires equal treatment for spouses, domestic partners, and dependents, and preserves coverage when contraception is used for non-contraceptive medical purposes such as treating menopause symptoms or reducing ovarian cancer risk. The bill excludes RU-486 from the mandate and allows a narrow religious-employer exemption for church or church-controlled organizations, with notice requirements to enrollees.
The bill’s impact on state law would be to amend Rhode Island’s insurance and Medicaid statutes to create a broad, uniform contraceptive-coverage mandate and to add enforcement and oversight duties for the insurance commissioner and the executive office of health and human services. Those agencies would be required to adopt regulations, conduct stakeholder meetings, perform random compliance reviews, and issue annual public reports. Insurers that violate the mandate would be subject to existing statutory penalties under the relevant insurance chapters.
Overall sentiment appears supportive of expanded contraceptive access, based on the bill’s broad coverage requirements, consumer-protection features, and explicit inclusion of over-the-counter products and extended dispensing. No committee transcript or vote record was provided, so there is no recorded floor or committee debate to indicate opposition or support beyond the bill’s text and sponsorship. The structure of the bill suggests an intent to standardize access and reduce out-of-pocket barriers rather than to narrow coverage.
The main points of contention likely involve the scope of the mandate, the cost implications for insurers and health plans, the treatment of religious employers, and the exclusion of RU-486. The bill also creates potential administrative concerns by requiring rulemaking, stakeholder engagement, and compliance reviews across several regulatory regimes. Any debate would likely center on balancing contraceptive access and consumer protections against premium impacts, plan administration, and religious-liberty objections.
H7323 would amend Rhode Island General Laws chapters 27-18, 27-19, 27-20, 27-41, and 40-8 to require comprehensive contraceptive coverage in private insurance and Medicaid. It would mandate coverage for FDA-approved contraceptives, therapeutic equivalents, sterilization, counseling, and follow-up services, prohibit most cost-sharing and utilization controls, require 12-month dispensing, and establish enforcement, rulemaking, and reporting duties for state regulators. The bill would apply to policies and plans delivered, issued, renewed, amended, or effective on or after January 1, 2027, with a separate effective date upon passage.
The bill’s overall tone is pro-access and consumer-protective, with a clear emphasis on expanding reproductive health coverage and reducing barriers to obtaining contraception. Because no committee transcripts or votes were provided, there is no documented public debate in the record supplied here. Based on the text, the bill appears designed to be broadly inclusive of insured individuals and dependents while preserving a limited religious exemption.
Likely areas of contention include whether insurers and public programs should be required to cover all FDA-approved contraceptives without cost-sharing, whether the mandate could increase premiums or administrative burdens, and whether the religious-employer exemption is too narrow or too broad. The exclusion of RU-486 may also draw attention from advocates on either side. Additional friction may arise over the bill’s restrictions on medical management, the requirement to cover over-the-counter contraceptives at point of sale, and the new compliance-review and reporting obligations placed on state agencies.